other material
confidence high
sentiment positive
materiality 0.75
Tectonic TX45 Phase 1b in PH-HFpEF shows 19% PCWP reduction, sustained 29-day effects
Tectonic Therapeutic, Inc.
- Single IV dose of TX45 reduced PCWP by 19.0% [95% CI, -26.1% to -11.9%] in 19-patient cohort.
- In CpcPH subgroup (PVR≥2), PVR decreased 32.0% (≥2) and 35.5% (≥3); 30%+ reduction in PVR.
- Echocardiogram showed sustained improvements in TAPSE/SPAP and RVFAC for 29 days post-dose.
- Cardiac output increased 18.5% overall; greater improvement in patients with higher baseline PVR.
- No serious or severe adverse events; Phase 1b Part B in HFrEF topline expected H2 2025.